ATE404669T1 - In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide - Google Patents

In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Info

Publication number
ATE404669T1
ATE404669T1 AT01926595T AT01926595T ATE404669T1 AT E404669 T1 ATE404669 T1 AT E404669T1 AT 01926595 T AT01926595 T AT 01926595T AT 01926595 T AT01926595 T AT 01926595T AT E404669 T1 ATE404669 T1 AT E404669T1
Authority
AT
Austria
Prior art keywords
differentially expressed
breast
bladder cancer
polypeptides encoded
present
Prior art date
Application number
AT01926595T
Other languages
German (de)
English (en)
Inventor
Maurice Zauderer
Elizabeth Evans
Melinda Borrello
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE404669T1 publication Critical patent/ATE404669T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01926595T 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide ATE404669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04

Publications (1)

Publication Number Publication Date
ATE404669T1 true ATE404669T1 (de) 2008-08-15

Family

ID=22717696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926595T ATE404669T1 (de) 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Country Status (10)

Country Link
US (3) US7268207B2 (enExample)
EP (1) EP1272636B8 (enExample)
JP (1) JP2004502408A (enExample)
CN (2) CN101643732A (enExample)
AT (1) ATE404669T1 (enExample)
AU (2) AU2001253119B2 (enExample)
CA (1) CA2413211A1 (enExample)
DE (1) DE60135315D1 (enExample)
NZ (1) NZ522282A (enExample)
WO (1) WO2001074859A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253119B2 (en) * 2000-04-04 2006-04-13 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
US20020164346A1 (en) * 2001-02-14 2002-11-07 Nicolette Charles A. Altered peptide ligands
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
AU2004296184B2 (en) * 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
WO2007149586A2 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
WO2008103392A2 (en) * 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
CN107619804A (zh) 2009-01-08 2018-01-23 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
US8808693B2 (en) * 2009-04-01 2014-08-19 The University Of British Columbia Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
WO2011038142A2 (en) 2009-09-24 2011-03-31 The Regents Of The University Of California Bladder cancer specific ligand peptides
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
TWI765875B (zh) * 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
CA3073812A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. Neoantigen identification for t-cell therapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
US12359253B2 (en) 2018-04-09 2025-07-15 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing
KR102318018B1 (ko) 2019-07-05 2021-10-28 한국생산기술연구원 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드
WO2021076770A1 (en) * 2019-10-18 2021-04-22 The Board Of Trustees Of The Leland Stanford Junior University Clinical- and industrial-scale intact-tissue sequencing
CN115407064B (zh) * 2021-05-26 2025-09-23 复旦大学附属肿瘤医院 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途
US20240409582A1 (en) * 2022-08-23 2024-12-12 The University of North Texas Health Sciences Cente Design and characterization of inhibitory peptides (ipeps) derived from of mien 1 protein sequence

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (ja) * 1991-04-18 1993-04-02 Fujitsu Ltd 双曲線航法システムにおけるシステム監視処理方式
SG52492A1 (en) 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU2342299A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
AU2001253119B2 (en) * 2000-04-04 2006-04-13 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1274852A2 (en) 2000-04-12 2003-01-15 University Of Rochester Targeted vaccine delivery systems
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CN1306272C (zh) * 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US20050042218A1 (en) 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
AU2004296184B2 (en) * 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Also Published As

Publication number Publication date
NZ522282A (en) 2005-03-24
WO2001074859A2 (en) 2001-10-11
US7910551B2 (en) 2011-03-22
DE60135315D1 (de) 2008-09-25
CN1610743A (zh) 2005-04-27
AU2001253119B2 (en) 2006-04-13
US20020155447A1 (en) 2002-10-24
CN101643732A (zh) 2010-02-10
US7268207B2 (en) 2007-09-11
US20090312263A1 (en) 2009-12-17
EP1272636B1 (en) 2008-08-13
JP2004502408A (ja) 2004-01-29
EP1272636A2 (en) 2003-01-08
US20070081942A1 (en) 2007-04-12
WO2001074859A3 (en) 2002-03-28
AU5311901A (en) 2001-10-15
CA2413211A1 (en) 2001-10-11
EP1272636B8 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
ATE404669T1 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO2002016413A8 (en) Cripto tumour polypeptide
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
PT1200590E (pt) Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
IL149046A (en) Composition comprising a polynucleotide encoding a 36p6d5 polypeptide for use in diagnosing cancer and diagnostic method related to 36p6d5
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
EP2070949A3 (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
MX2021004425A (es) Vacuna contra cancer de cadena invariante de teleosteo.
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
TR200101702T2 (tr) Mammaglobin, göğse özgü salgılanan bir göğüs kanseri proteini.
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
JP2005524719A5 (enExample)
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE206129T1 (de) Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
WO2002066506A3 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
WO2003024302A3 (en) Detection and treatment of cancers of breast
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties